DMW - Deutsche Medizinische Wochenschrift, Inhaltsverzeichnis Dtsch Med Wochenschr 2012; 137(49): 2567-2570DOI: 10.1055/s-0032-1327332 Nephrologie | Commentary Nephrologie, Transplantationsmedizin © Georg Thieme Verlag KG Stuttgart · New York Dialysetherapie und Nierentransplantation Update 2012Dialysis and renal transplantationUpdate 2012 W. Riegel 1 Medizinische Klinik III, Klinikum Darmstadt , B. Krüger 2 V. Medizinische Klinik, Universitätsklinikum Mannheim , P. Schnülle 3 Nierenzentrum Weinheim › Institutsangaben Artikel empfehlen Abstract Artikel einzeln kaufen Schlüsselwörter SchlüsselwörterPeritonealdialyse - Hygiene - Sirolimus - Betalacept - mesenchymale Stammzellen Keywords Keywordsperitoneal dialysis - hygiene - sirolimus - betalacept - mesenchymal stem cells Volltext Referenzen Literatur 1 Campbell SB, Walker R, Tai SS et al. Randomized controlled trial of sirolimus for renal transplant recipients at high risk for nonmelanoma skin cancer. Am J Transplant 2012; 12: 1146-1156 2 Cnossen TT, Kooman JP, Krepel HP et al. Prospective study on clinical effects of renal replacement therapy in treatment-resistant congestive heart failure. NephrolDial Transplant 2012; 27: 2794-2799 3 Dalrymple LS, Katz R, Kestenbaum B et al. The risk of infection-related hospitalization with decreased kidney function. Am J Kidney Dis 2012; 59: 356-363 4 Euvrard S, Morelon E, Rostaing L et al. TUMORAPA Study Group. Sirolimus and secondary skin-cancer prevention in kidney transplantation. N Engl J Med 2012; 367: 329-339 5 James MT, Quan H, Tonelli M et al. CKD and risk of hospitalization and death with pneumonia. Am J Kidney Dis 2009; 54: 24-32 6 Montgomery RA, Lonze BE, King KE et al. Desensitization in HLA-incompatible kidney recipients and survival. N Engl J Med 2011; 365: 318-326 7 Núñez J, González M, Miñana G et al. Continuous ambulatory peritoneal dialysis as a therapeutic alternative in patients with advanced congestive heart failure. Eur J Heart Fail 2012; 14: 540-548 8 Pestana JO, Grinyo JM, Vanrenterghem Y et al. Three-year outcomes from BENEFIT-EXT: a phase III study of belatacept versus cyclosporine in recipients of extended criteria donor kidneys. Am J Transplant 2012; 12: 630-639 9 Sens F, Schott-Pethelaz AM, Labeeuw M et al. on behalf of the REIN Registry. Survival advantage of hemodialysis relative to peritoneal dialysis in patients with end-stage renal disease and congestive heart failure. Kidney Int 2011; 80, 970-977 10 Tan J, Wu W, Xu X et al. Induction therapy with autologous mesenchymal stem cells in living-related kidney transplants. JAMA 2012; 307: 1169-1177 11 Vincenti F, Larsen CP, Alberu J et al. Three-year outcomes from BENEFIT, a randomized, active-controlled, parallel-group study in adult kidney transplant recipients. Am J Transplant 2012; 12: 210-217
